The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. This is an ASCO Meeting ...
Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary ...
To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. This guideline update ...
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...
Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is a rare peripheral T-cell lymphoma associated with Epstein-Barr virus. It most often presents as limited-stage disease in patients of East ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by the author of ...
High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...
Comics: Educating and introducing children to radiation therapy. This is an ASCO Meeting Abstract from the 2018 Palliative and Supportive Care in Oncology Symposium. This abstract does not include a ...
Outcomes of EGFR-TKI therapy in EGFR mutated metastatic lung adenocarcinoma in an inner city population. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not ...
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results